Approaches for genetic engineering ofrhabdoviruses such as VSV and paramyxoviruses such as SV5 haveproven to be more complex than those used for many other RNA viruses. This is due to inherent properties ofthe negative strand RNA virus genome and growth cycle, both of which present challenges to construction ofdefined vectors that are not solved by traditional recombinant DNA approaches. However, recent state-of-the-art technologies have been developed to overcome these obstacles and these approaches now allow thegeneration of recombinant negative strand RNA viruses containing pre-determined alterations to theirgenomes. The Virology Core Laboratory of the Program will function as a resource to carry out these newapproaches in order to facilitate the generation and purification of novel recombinant viruses for Projects 2and 3. In addition, the Core will function as a source of purified virus preparations that are of a consistenthigh quality for use in the vaccination experiments propose in all four Projects.The goal of the Virology Core Laboratory of the Program is to perform a consistent, uniform and highquality set of tasks needed by each of the four Projects, including recovery of recombinant viruses,defining growth and gene expression properties, and providing viral stocks for vaccination of mice.
In aim1, the Core will use state-of-the-art technologies to facilitate the rapid and consistent recovery ofrSV5 andrVSV vectors from engineered plasmid DNA.
In aim 2, the Core will carry out assays for single step andmulti-step growth, establishing viral RNA synthesis profiles and determining the properties of foreign geneexpression.
In aim 3, the Core will carry out the purification of virus stocks, titrating of stocks and qualitycontrol assays for the levels of contaminationCompletion of these tasks will assure a reproducible and dependable source of viral vectors for the ProgramProject such that comparisons can be made across Projects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI060642-04
Application #
7447882
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
4
Fiscal Year
2007
Total Cost
$150,434
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Beauchamp, Nicole M; Yammani, Rama D; Alexander-Miller, Martha A (2012) CD8 marks a subpopulation of lung-derived dendritic cells with differential responsiveness to viral infection and toll-like receptor stimulation. J Virol 86:10640-50
Clark, Kimberly M; Johnson, John B; Kock, Nancy D et al. (2011) Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Virology 419:97-106
Bates, John T; Graff, Aaron H; Phipps, James P et al. (2011) Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J Immunol 186:6255-62
Ahmed, Maryam; Puckett, Shelby; Arimilli, Subhashini et al. (2010) Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol 84:12093-8
Manuse, Mary J; Briggs, Caitlin M; Parks, Griffith D (2010) Replication-independent activation of human plasmacytoid dendritic cells by the paramyxovirus SV5 Requires TLR7 and autophagy pathways. Virology 405:383-9
Beauchamp, Nicole M; Busick, Rhea Y; Alexander-Miller, Martha A (2010) Functional divergence among CD103+ dendritic cell subpopulations following pulmonary poxvirus infection. J Virol 84:10191-9
Braxton, Cassandra L; Puckett, Shelby H; Mizel, Steven B et al. (2010) Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol 84:3552-61
Mizel, Steven B; Bates, John T (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677-82
Delaney, Kristen N; Phipps, James P; Johnson, John B et al. (2010) A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol 23:201-10
Palmer, Ellen M; Holbrook, Beth C; Arimilli, Subhashini et al. (2010) IFNgamma-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment. Virology 404:225-30

Showing the most recent 10 out of 25 publications